Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor: Amgen
This observational or N/A phase trial investigates Atherosclerotic Cardiovascular Disease and Obesity and is currently actively recruiting participants. Amgen leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .